These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1151 related items for PubMed ID: 15502600

  • 1. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [Abstract] [Full Text] [Related]

  • 2. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H.
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group.
    Biol Psychiatry; 2007 Jun 15; 61(12):1380-7. PubMed ID: 17137560
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, West SA, Sangal RB, Bohan TP, Zeldis JB.
    J Child Adolesc Psychopharmacol; 2004 Jun 15; 14(4):542-54. PubMed ID: 15662146
    [Abstract] [Full Text] [Related]

  • 7. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
    Weiss M, Wasdell M, Patin J.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov 15; 43(11):1415-21. PubMed ID: 15502601
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 15; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar 15; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 10. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network.
    Arch Gen Psychiatry; 2005 Nov 15; 62(11):1266-74. PubMed ID: 16275814
    [Abstract] [Full Text] [Related]

  • 11. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A.
    Psychopharmacol Bull; 2008 Nov 15; 41(1):19-33. PubMed ID: 18362868
    [Abstract] [Full Text] [Related]

  • 12. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA, Blondis TA, Schnitzler ER, O'Brien T, Fishkin J, Blackwell B, Szumowski E, Roizen NJ.
    Pediatrics; 1996 Oct 15; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec 15; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 14. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May 15; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 15. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 15; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 16. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 15; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 17. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

  • 18. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb 01; 34(1):76-80. PubMed ID: 19815048
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Feb 01; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 20. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.
    Biol Psychiatry; 2008 May 15; 63(10):981-9. PubMed ID: 18206857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.